Please login to the form below

Not currently logged in
Email:
Password:

Cellerant appoints William Reed as VP clinical development

Will lead development of stem cell-based treatments for blood conditions and cancer

US biotech Cellerant Therapeutics has named Dr William Reed as VP, clinical development.

Dr Reed joins from Cerus Corporation and will lead the development of Cellerant's stem cell-based cellular and antibody therapies for blood disorders and cancer.

He has previous experience in treatments for blood conditions, spending time as director, clinical research and medical affairs at Cerus, where he worked on a programme for sickle cell disease.

Dr Reed was also an investigator at Blood Systems Research Institute in San Francisco and a medical director of the Human Islet and Cellular Transplantation Facility at University of California, San Francisco (UCSF).

Ram Mandalam, president and CEO of Cellerant, said:"His extensive experience in paediatric haematology/oncology and transfusion medicine will significantly benefit Cellerant in the development of CLT-008 for cord blood transplantation, leukaemia and acute radiation syndrome applications and the future clinical development of our cancer stem cell programme.”

15th February 2013

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

ACCOMPLISH MEANINGFUL HCP ENGAGEMENT ONLINE
The art of delivering valuable customer journeys aligned to your key messages in 2020...
DEMAND DIVERSITY REPORT 01: Exploring attitudes towards clinical research among people from different ethnic groups in the UK
This report reveals insights from the people themselves, and discusses the starting points for overcoming current challenges....
Why are new medicinal products denied reimbursement in France?
Many medicinal products looking to launch are rejected for reimbursement in France. A manufacturer must convince the Transparency Committee that their product is safe, effective and offers added value relative...

Infographics